Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437276 | 0.94 | HSD11B1 (0.41) | HSD11B1HTTL3MBTL1HTR2ACYP2D6 | |
| SCHEMBL14092992 | 0.85 | HSD11B1 (0.43) | HSD11B1CYP2D6CYP1A2 | |
| SCHEMBL12560562 | 0.85 | HSD11B1 (0.43) | HSD11B1CYP2D6CYP1A2 | |
| SCHEMBL3477269 | 0.78 | HSD11B1 (0.36) | HSD11B1L3MBTL1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL6784201 | 0.78 | DRD2 (0.47) | DRD2DRD3 | |
| SCHEMBL23108745 | 0.78 | HSD11B1 (0.36) | HSD11B1L3MBTL1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL23132919 | 0.78 | HSD11B1 (0.36) | HSD11B1L3MBTL1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL23995928 | 0.78 | HSD11B1 (0.49) | HSD11B1HTTL3MBTL1CYP2D6CYP1A2 | |
| SCHEMBL22142323 | 0.78 | HSD11B1 (0.49) | HSD11B1HTTL3MBTL1CYP2D6CYP1A2 | |
| SCHEMBL18199673 | 0.78 | HSD11B1 (0.49) | HSD11B1HTTL3MBTL1CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683297-B2 | Substituted heteroaryl compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190152977-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | Northern Industrial Area, (CN) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152977-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | PRKACA, PRKDC, PRKACB | HSD11B1 1278/4885HTT 660/4885L3MBTL1 2514/4885 |
| US-10683297-B2 | Substituted heteroaryl compounds and methods of use | PRKACA, PRKDC, PRKACB | HSD11B1 1278/4885HTT 660/4885L3MBTL1 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.